Effect of single nucleotide polymorphism of XRCC1 gene on the sensitivity of capecitabine combined with oxaliplatin as first line chemotherapy in gastric cancer patients

Hui SUN,Jin-fei CHEN,Yue-yu FANG,Xin-guang TAN,Ting-yun CUI,Lian-hua JI

DOI: https://doi.org/10.3969/j.issn.1003-6350.2016.04.004

2016-01-01

Abstract:Objective To investigate the effect of single nucleotide polymorphism of XRCC1Arg194Trp and Arg399Gln genes on the sensitivity of capecitabine combined with oxaliplatin as first line chemotherapy in patients with gastric cancer. Methods Eighty-six patients pathologically confirmed as advanced gastric cancer in our hospital from Jan. 2013 to Jun. 2014 were enrolled in the study, which were all treated with capecitabine combined with oxaliplatin chemotherapy. The clinical effects were evaluated after 3 cycles of treatment. The clinical data and peripheral blood sam-ples were collected, and genotyping of XRCC1Arg194Trp and Arg399Gln were performed by using TaqMan-MGB probe. Then the effects of treatment were compared between different genotypes. Results Among the 86 patients, 52 (60.5%) were sensitive to chemotherapy. At XRCC1Arg194Trp locus, the patients carrying Trp (Arg/Trp+Trp/Trp) geno-type had the sensitivity to chemotherapy of 70.8%, and the patients carrying Arg/Arg genotype had the sensitivity of 47.4%, P=0.027. The median time to progression (TTP) was 9.48 months for patients with Trp genotype and 7.36 months for those with Arg/Arg genotype, P=0.024. The risk of drug resistance for Arg/Arg genotype was significantly higher than that of Trp genotype (OR:2.84, 95%CI:0.772~4.313, P=0.031). At XRCC1Arg399/Arg locus, the patients carrying Arg/Arg genotype had the sensitivity of 72.5%, and the patients carrying Gln (Arg/Gln+Gln/Gln) genotype had the sensitivity to chemotherapy of 42.9%, P=0.007. The median TTP was 10.26 months for patients with Arg/Arg geno-type and 8.03 months for those with Gln genotype, P=0.012. The risk of drug resistance for Gln genotype was signifi-cantly higher than that of Arg/Arg genotype (OR:4.62, 95%CI:1.637~7.201, P=0.012). Conclusion Single nucleotide polymorphism of XRCC1Arg194Trp, Arg399Gln gene maybe associated with the sensitivity of capecitabine combined with oxaliplatin chemotherapy.